Cargando…
Erratum: A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells
Autores principales: | Cheadle, E J, Lipowska-Bhalla, G, Dovedi, S J, Fagnano, E, Klein, C, Honeychurch, J, Illidge, T M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609297/ https://www.ncbi.nlm.nih.gov/pubmed/28751765 http://dx.doi.org/10.1038/leu.2017.218 |
Ejemplares similares
-
A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells
por: Cheadle, E J, et al.
Publicado: (2017) -
The anti-tumor immune response generated by radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade
por: Dovedi, Simon, et al.
Publicado: (2014) -
Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies
por: Fagnano, Ester, et al.
Publicado: (2023) -
Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations
por: Colton, Madyson, et al.
Publicado: (2020) -
Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy
por: Dovedi, Simon J., et al.
Publicado: (2016)